AB
OCUL icon

Amalgamated Bank’s Ocular Therapeutix OCUL Stock Holding History

Amalgamated Bank’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,846
Closed -$71K – 2442
2025
Q4 		$71K Buy
5,846
+1,292
+28% +$15.7K ﹤0.01% 1752
2025
Q3 		$53K Sell
4,554
-848
-16% -$10.1K ﹤0.01% 1824
2025
Q2 		$50K Hold
5,402
– – ﹤0.01% 1826
2025
Q1 		$40K Buy
5,402
+18
+0.3% +$138 ﹤0.01% 1841
2024
Q4 		$46K Hold
5,384
– – ﹤0.01% 1854
2024
Q3 		$47K Hold
5,384
– – ﹤0.01% 1867
2024
Q2 		$37K Buy
5,384
+1,481
+38% +$9.14K ﹤0.01% 1929
2024
Q1 		$36K Sell
3,903
-7,184
-65% -$51K ﹤0.01% 1945
2023
Q4 		$49K Sell
11,087
-794
-7% -$2.35K ﹤0.01% 2259
2023
Q3 		$37K Hold
11,881
– – ﹤0.01% 2379
2023
Q2 		$61K Buy
11,881
+1,137
+11% +$6.76K ﹤0.01% 2243
2023
Q1 		$57K Sell
10,744
-1,616
-13% -$7.67K ﹤0.01% 2259
2022
Q4 		$35K Hold
12,360
– – ﹤0.01% 2579
2022
Q3 		$51K Buy
12,360
+196
+2% +$987 ﹤0.01% 2451
2022
Q2 		$49K Sell
12,164
-355
-3% -$1.34K ﹤0.01% 2497
2022
Q1 		$62K Sell
12,519
-1,013
-7% -$5.62K ﹤0.01% 2370
2021
Q4 		$94K Sell
13,532
-253
-2% -$1.97K ﹤0.01% 2069
2021
Q3 		$138K Sell
13,785
-690
-5% -$7.75K ﹤0.01% 2047
2021
Q2 		$205K Buy
14,475
+4,203
+41% +$63.9K ﹤0.01% 2022
2021
Q1 		$169K Sell
10,272
-390
-4% -$7.51K 0.01% 1517
2020
Q4 		$221K Buy
+10,662
New +$158K 0.01% 1395

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Amalgamated Bank's OCUL Position: Q1 2026 in Review

Amalgamated Bank sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 5,846 shares — an estimated $71K sold.

Amalgamated Bank first reported a position in OCUL in Q4 2020 and held it in 21 quarters. The position peaked at $221K in Q4 2020. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Amalgamated Bank reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 5,846 Ocular Therapeutix shares in Q1 2026, an estimated $71K.
  • Amalgamated Bank first reported a position in Ocular Therapeutix in Q4 2020 and held it in 21 quarters.
  • Amalgamated Bank's Ocular Therapeutix position peaked at $221K in Q4 2020.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.